Comparing the current results to its competitors, Calliditas Therapeutics Ab reported Revenue increase in the 4 quarter 2023 by 49.74 % year on year, while most of its competitors have experienced contraction in revenues by -32.76 %, achieved in the same quarter.
Calliditas Therapeutics Ab, slower than the average decrease reported by the company's competitors of -61.55 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -61.55 %
Calliditas Therapeutics Ab's Comment on Competition and Industry Peers
The company operates in a highly competitive biopharmaceutical market that includes established pharmaceutical companies, biotechnology firms, universities, and other research or commercial institutions. Competitors often possess significantly greater financial, research, and development resources, as well as extensive experience in clinical testing, regulatory approvals, patient recruitment, and manufacturing. Specific competitors referenced include go and Nefecon, particularly in relation to patient population considerations.
Due to outstanding performance in Overall company, revenue grew by 49.74 % Calliditas Therapeutics Ab improved its market share, to approximately 0.23 %.
March 6, 2024
Calliditas Therapeutics AB, a renowned pharmaceutical company, recently made a groundbreaking announcement that has sent ripples of excitement throughout the medical community. The US Food and Drug Administration (FDA) has granted an additional seven-year orphan drug exclusivity period for Calliditas revolutionary drug, TARPEYO. This exclusive period, set to expire in December 2030, marks a significant milestone in the treatment of a rare, debilitating disease.TARPEYO has emerged as a highly promising therapy for a previously underserved patient population. The FDA s decision to extend the orphan drug exclusivity period is a testament to the drug s exceptional potential in treating this rare disease. Orphan...
Publicly Traded Peers of Calliditas Therapeutics Ab
Ardelyx inc Share Performance
+1.07%
Over The Past 5 Days
Ardelyx inc
Profile
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Sarepta Therapeutics Inc's business model centers around the research, development, and commercialization of innovative genetic medicines for rare diseases, with a particular focus on Duchenne muscular dystrophy (DMD).
Sources:
Calliditas Therapeutics Ab’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Calliditas Therapeutics Ab versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
